Jaumdally Rumi J, Varma Chetan, Blann Andrew D, MacFadyen Robert J, Lip Gregory Y H
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Ann Med. 2007;39(4):298-305. doi: 10.1080/07853890701298132.
Vascular growth factors are involved in the pathophysiology of human atherosclerotic vascular disease and plaque destabilization. We hypothesized that in stable patients with coronary artery disease (CAD), plasma levels of vascular endothelial growth factor (VEGF) and angiopoietins 1 and 2 (as indices of angiogenesis) would be no higher in coronary sinus blood when compared to the aortic root, coronary ostium, and peripheral femoral vein. Secondly, we hypothesized that percutaneous coronary intervention (PCI; angioplasty+/-stenting) would increase intracardiac levels of these indices, perhaps by destabilizing coronary plaques.
Patients undergoing elective diagnostic coronary angiography (n = 70; mean age 58.8+/-11.2 years) of which 37 proceeded to PCI were recruited. Blood samples were obtained from the aortic root, coronary ostium, coronary sinus, and femoral vein. Plasma VEGF, angiopoietin-1 and angiopoietin-2 levels were measured by immunoassays.
There were no significant differences in VEGF, angiopoietin-1 and angiopoietin-2 levels when aortic root, coronary ostium, coronary sinus, and femoral vein samples were compared (P = not significant (NS)). In patients undergoing PCI, peripheral angiopoietin-2 levels were increased significantly post PCI (P = 0.01). There was also a difference in intracardiac gradient (that is, aortic root-coronary sinus difference) in angiopoietin-1 (P = 0.02) following PCI. No significant changes in VEGF with PCI were noted.
There were no differences in indices of angiogenesis when aortic root, coronary ostium, coronary sinus, and femoral vein levels of VEGF and angiopoietins are compared, suggesting that peripheral blood measurements of these indices are comparable to intracardiac levels. Although no immediate effects were observed in soluble VEGF levels, PCI affected intracardiac angiopoietin-1 with a systemic release of angiopoietin-2. Further investigations are necessary to determine the relative systemic and intracardiac effects of the angiopoietins in vascular remodelling post PCI.
血管生长因子参与人类动脉粥样硬化性血管疾病的病理生理过程和斑块不稳定。我们假设,在稳定型冠心病(CAD)患者中,与主动脉根部、冠状动脉开口和外周股静脉相比,冠状窦血中血管内皮生长因子(VEGF)以及血管生成素1和2(作为血管生成指标)的血浆水平不会更高。其次,我们假设经皮冠状动脉介入治疗(PCI;血管成形术±支架置入术)会增加这些指标的心脏内水平,可能是通过使冠状动脉斑块不稳定来实现。
招募接受选择性诊断性冠状动脉造影的患者(n = 70;平均年龄58.8±11.2岁),其中37例进行了PCI。从主动脉根部、冠状动脉开口、冠状窦和股静脉采集血样。通过免疫测定法测量血浆VEGF、血管生成素-1和血管生成素-2水平。
比较主动脉根部、冠状动脉开口、冠状窦和股静脉样本时,VEGF、血管生成素-1和血管生成素-2水平无显著差异(P =无显著性差异(NS))。在接受PCI的患者中,外周血管生成素-2水平在PCI后显著升高(P = 0.01)。PCI后血管生成素-1的心脏内梯度(即主动脉根部 - 冠状窦差异)也有差异(P = 0.02)。未观察到PCI后VEGF有显著变化。
比较主动脉根部、冠状动脉开口、冠状窦和股静脉的VEGF和血管生成素水平时,血管生成指标无差异,这表明这些指标的外周血测量结果与心脏内水平相当。虽然可溶性VEGF水平未观察到即时效应,但PCI影响了心脏内血管生成素-1并伴有血管生成素-2的全身释放。有必要进一步研究以确定血管生成素在PCI后血管重塑中的相对全身和心脏内效应。